Teladoc Health (NYSE:TDOC) Issues Q4 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its fourth quarter 2026 earnings guidance on Friday. The company provided EPS guidance of -0.230–0.030 for the period, compared to the consensus earnings per share estimate of -0.090. The company issued revenue guidance of $569.0 million-$615.0 million, compared to the consensus revenue estimate of $601.7 million. Teladoc Health also updated its FY 2026 guidance to -0.950–0.750 EPS.

Teladoc Health Price Performance

Shares of Teladoc Health stock opened at $8.88 on Friday. The company has a market capitalization of $1.61 billion, a PE ratio of -10.40 and a beta of 2.14. The business has a 50-day moving average of $6.19 and a 200-day moving average of $6.47. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.89.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The business had revenue of $605.10 million for the quarter, compared to analyst estimates of $588.14 million. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.52%. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.28) EPS. On average, equities analysts expect that Teladoc Health will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Bank of America boosted their price objective on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Needham & Company LLC restated a “hold” rating on shares of Teladoc Health in a research report on Thursday. Canaccord Genuity Group lowered their price target on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Stifel Nicolaus upped their price objective on Teladoc Health from $5.50 to $6.50 and gave the company a “hold” rating in a report on Thursday. Finally, Citigroup decreased their target price on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research note on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Teladoc Health currently has a consensus rating of “Hold” and a consensus target price of $7.54.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles III sold 17,805 shares of Teladoc Health stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the completion of the sale, the chief executive officer directly owned 465,535 shares in the company, valued at $2,839,763.50. The trade was a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.70% of the company’s stock.

Key Headlines Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported third-quarter revenue of $605.1 million, ahead of the approximately $588 million consensus estimate, while its $0.15 per-share loss was narrower than the expected $0.22 loss. Revenue still declined about 3% year over year, but the results exceeded expectations. Teladoc Health Reports Third Quarter 2026 Results
• Positive Sentiment: Adjusted EBITDA reached approximately $79 million, near the high end of management’s prior outlook, and cash-flow improvement made the quarterly loss appear higher quality to investors. Teladoc Health Stock Rebounds on Q3 Results as Cash Flow Improves
• Positive Sentiment: BetterHelp generated $32 million of insurance revenue in the quarter. Management also highlighted a target insurance-related run rate of at least $200 million, supporting hopes that the mental-health business can diversify beyond direct consumer payments. Teladoc: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: The company plans to repurchase convertible notes, which could reduce debt-related obligations and signal confidence in its balance-sheet position. Teladoc Targets BetterHelp Insurance Run Rate and Plans Note Repurchase
• Neutral Sentiment: Unusually heavy call-option activity and the stock’s move above its 200-day moving average likely amplified the rally, but these are trading signals rather than changes to the company’s fundamentals.
• Negative Sentiment: Fourth-quarter revenue guidance of $569 million to $615 million has a midpoint below the $601.7 million consensus estimate. Full-year 2026 EPS guidance of a $0.75 to $0.95 loss also brackets the consensus estimate of a $0.81 loss, underscoring that Teladoc remains unprofitable and growth remains pressured.
• Negative Sentiment: Analyst support remains cautious: Stifel raised its price target to $6.50 but maintained a “hold” rating, implying substantial downside from the recent trading level.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.